Cerebral palsy affects approximately 17 million people worldwide, making it the most common cause of physical disability in childhood. Yet for most families and clinicians, management tends to center on symptom control — physiotherapy, antispasticity medications, surgical procedures — with relatively little attention to the biological signals that drive individual variation in outcomes.

Amyotrophic lateral sclerosis is one of the most challenging diagnoses in neurology. It moves fast, it speaks loudly, and it leaves patients, families, and clinicians searching for traction in an area where traction has historically been difficult to find.

Living with hereditary spastic paraplegia, or watching a family member navigate its progression, brings a particular kind of uncertainty. The condition moves slowly enough that it can feel manageable one year, then noticeably different the next.

Stiff-Person Syndrome sits in a strange place in medicine. It is rare enough that many neurologists encounter only a handful of cases in a career, yet for those living with it, the muscle rigidity, unpredictable spasms, and relentless anxiety can make ordinary life feel genuinely unmanageable.

Most information available on primary lateral sclerosis falls into one of two categories: a clinical definition copied from a textbook, or reassurance that "it progresses more slowly than ALS." Neither of those helps much when you are the one waking up at 3 a.m.

If you or someone you care about has been diagnosed with HTLV-1-associated myelopathy/tropical spastic paraparesis (HAM/TSP), you've probably already noticed a gap. The diagnosis explains the mechanism in broad strokes — a retrovirus, a chronic immune response, slow damage to the spinal cord — but it rarely tells you what to actually watch, measure, or ask your neurologist about next.